CCL3 and B-cell chronic lymphocytic leukemia: These data suggest that pirtobrutinib’s pharmacokinetic/pharmacodynamic profile during therapy was sufficient to result in initial mechanistic inhibition of BCR pathway in CLL cells with a decline in CCL3/CCL4 biomarkers among diverse BTK backgrounds.